Abstract

Contrasting data have been reported so far on the role played by γ-aminobutyric acid (GABA) in the control of PRL secretion in the rat. Based on the findings that systemic administration of muscimol (M), a powerful agonist at GABA receptors, lowered plasma PRL in male rats, studies were undertaken to determine both the mechanism (s) of M-induced inhibition of plasma PRL and the reason (s) for the disparity between data pointing to a stimulatory and those favoring an inhibitory role of GABA on PRL secretion. In freely behaving male rats, administration of either picrotoxin (PICRO; 1 mg/kg, iv) or bicuculline (BIC; 0.4 mg/kg, iv), two GABA antagonist drugs, failed to counteract and instead potentiated the PRL-lowering effect of M (2.0 mg/kg, iv). BIC alone decreased baseline PRL levels. In ovariectomized estrogenprimed rats, PICRO and BIC, at the same doses, elicited a striking decline of the elevated basal PRL levels and were again unable to oppose the effect of M. In contrast to its effect after systemic injection, M (500 ng) injected into the lateral ventricle of freely behaving male rats elicited a clear-cut rise in plasma PRL which was suppressed by BIC. The dual effect of M on PRL secretion according to the route of administration was indicative of an extra-central nervous system site of action of the drug when given systemically. In keeping with this hypothesis, M (2.5 × 10-5 M) inhibited PRL release from rat isolated anterior pituitaries (AP), an effect which was abolished by coincubation with equimolar doses of PICRO; however, M (2 mg/kg, iv) failed to lower plasma PRL levels in hypophysectomized rats bearing an ectopic AP. Also favoring a direct AP site of action for M was the observation that it completely abolished, after systemic administration (2 mg/kg, iv), the striking rise in plasma PRL exerted by a-methylparatyrosine, a drug which acts at the central nervous system level. Collectively, these data would demonstrate the existence of a dual GABAergic control of PRL secretion, one stimulatory, exerted through the central nervous system, and the other inhibitory, occurring at the level of the AP.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call